Urgent.News

600+ sources. One page. See who else covered it.

Thursday, 13 August 2026 Reading Room
Editions ▾
🌐 Global edition🇦🇷 Argentina🇦🇺 Australia🇧🇷 Brazil🇨🇦 Canada🇨🇴 Colombia🇫🇷 France🇩🇪 Germany🇬🇭 Ghana🇭🇰 Hong Kong🇮🇳 India🇮🇩 Indonesia🇮🇱 Israel🇯🇵 Japan🇰🇪 Kenya🇲🇾 Malaysia🇳🇬 Nigeria🇵🇰 Pakistan🇶🇦 Qatar🇷🇺 Russia🇸🇦 Saudi Arabia🇸🇬 Singapore🇿🇦 South Africa🇰🇷 South Korea🇪🇸 Spain🇹🇭 Thailand🇦🇪 UAE🇺🇦 Ukraine🇬🇧 United Kingdom🇺🇸 United States🇻🇳 Vietnam

Health & Medicine

BHEKISISA CROSSWORD #12

Think you know South Africa’s health system? Put your knowledge to the test with Bhekisisa’s health crossword. Drawing on years of reporting, investigations, data and policy coverage, the puzzle offers a fun way to explore the stories, issues and people that have shaped healthcare in South Africa. Stuck on a clue? The answers are waiting somewhere on […] The post BHEKISISA CROSSWORD #12 appeared…

bhekisisa.org ·

We haven't written up this one. Bhekisisa has the full story — the link below goes straight to it.

Read the original at bhekisisa.org →

More in Health & Medicine

Celltrion ADC Candidates Win FDA Fast Track

All three antibody-drug conjugate (ADC)-based anticancer new drug candidates being developed by Celltrion have been named targets for the Fast Track designation by the U.S.

  • Celltrion secures FDA Fast Track designation for three ADC candidates.
  • CT-P73 targets recurrent and metastatic cervical cancer.
  • Designation aims to expedite development and commercialization.

·businesskorea.co.kr

Novo Nordisk FDA Setback Creates Opportunity for Korean CDMOs

Denmark’s Novo Nordisk, which has led the global pharmaceutical and biotech market on the back of explosive demand for the obesity treatments Wegovy and Ozempic, has run into an unexpected hurdle as…

  • FDA withholds approval for Novo Nordisk facilities due to quality-control violations.
  • Novo Nordisk's Bloomington facility received critical observations, including sterility failures.
  • Korean CDMOs like Celltrion and Samsung Biologics benefit from regulatory challenges.

·businesskorea.co.kr